M&A Deal Summary

Telix Pharmaceuticals Acquires Artms

On March 5, 2024, Telix Pharmaceuticals acquired life science company Artms

Acquisition Highlights
  • This is Telix Pharmaceuticals’ 4th transaction in the Life Science sector.
  • This is Telix Pharmaceuticals’ 1st transaction in Canada.
  • This is Telix Pharmaceuticals’ 1st transaction in British Columbia.

M&A Deal Summary
Date 2024-03-05
Target Artms
Sector Life Science
Buyer(s) Telix Pharmaceuticals
Deal Type Add-on Acquisition

Target

Artms

Burnaby, British Columbia, Canada
Artms is a commercial-stage company that specializes in the physics, chemistry, and materials science of cyclotron-produced radionuclides. Its technology is used by the major manufacturing networks to optimize the production of a range of medical radioisotopes. Artms is based in Burnaby, British Columbia.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Telix Pharmaceuticals

North Melbourne, Australia
Category Company
Sector Life Science
DESCRIPTION

Telix Pharmaceuticals Ltd. is a clinical-stage biopharamaceutical company headquartered in Melbourne, Australia. Telix is developing an advanced portfolio of clinical-stage products that address significant unmet medical need in oncology, particularly renal, prostate and brain (glioblastoma) cancer.

DEAL STATS #
Overall 5 of 5
Sector (Life Science) 4 of 4
Type (Add-on Acquisition) 3 of 3
State (British Columbia) 1 of 1
Country (Canada) 1 of 1
Year (2024) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-02-27 IsoTherapeutics

Angleton, Texas, United States

IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services. IsoTherapeutics was founded in 2005 and is based in Angleton, Texas.

Buy -
Mergr

Product

Company

Legal